Topline data were announced from a phase 3b trial evaluating the concomitant use of ixekizumab and tirzepatide in adults with active psoriatic arthritis and obesity.
Combination therapy with ixekizumab and tirzepatide bested monotherapy with ixekizumab alone in both psoriatic arthritis and ...
GlobalData on MSN
Eli Lilly’s Taltz-Zepbound combo scores in late-stage PsA study
These results tout the potential of the combination as the new standard of care (SoC) for PsA patients with comorbid obesity.
The TOGETHER-PsA study shows that combining ixekizumab with tirzepatide leads to significantly better psoriatic arthritis ...
Management and Outcome Differences in Supraglottic Cancer Between Ontario, Canada, and the Surveillance, Epidemiology, and End Results Areas of the United States Purpose: To determine whether reverse ...
Clinical Trials—Real-World Data to Build a Future for Our Patients In the article that accompanies this editorial, Kwak et al 6 demonstrate using individual patient data from randomized trials that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback